Teriparatide Once Weekly Efficacy Research for primary prevention of Glucocorticoid-induced Osteoporosis

Teriparatide Once Weekly Efficacy Research for primary prevention of Glucocorticoid-induced Osteoporosis - TOWER-GO post hoc analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038035

Enrollment

Registered

2019-09-20

Start date

2019-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-induced osteoporosis (GIOP)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Objects who had not been taking oral steroid at a dose equivalent to 5mg/day of prednisolone or higher at least three months 2)Objects who was also treated by experimental drug with the once, and was estimated even sometime about the validity after treatment starting

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Rate of changes in bone mineral density of lumbar spine after 72 weeks	—

Secondary

Measure	Time frame
Rate of change in lumbar spine BMD after 24 and 48 weeks Ratio of the vertebral fractures Ratio of the non-vertebral fractures Rate of change in bone metabolism marker Rate of improvement in lower back pain Rate of improvement in QOL Adverse events	—

Countries

Japan

Contacts

Public ContactTerufumi Yokoyama

APO PLUS STATION Co., Ltd. CRO Business Division

t2-yokoyama@apoplus.co.jp03-6386-8800

Outcome results